Latisse® (bimatoprost ophthalmic solution 0.03%) is a prescription treatment designed to enhance eyelash growth and, increasingly, is used off-label for eyebrow regrowth. Originally developed as a glaucoma medication, bimatoprost was observed to stimulate hair growth, leading to its FDA approval for the treatment of eyelash hypotrichosis—an underdevelopment or loss of eyelashes. Today, it remains the only FDA-approved therapy proven to increase eyelash length, thickness, and darkness through a well-characterized biologic mechanism.
Bimatoprost works by modulating the hair growth cycle, specifically by prolonging the anagen (active growth) phase of hair follicles. Normally, eyelashes and eyebrow hairs cycle through growth (anagen), transition (catagen), and resting (telogen) phases. By extending the duration of anagen and increasing the number of hairs in this phase, bimatoprost enables follicles to produce longer, thicker, and more pigmented hairs over time. Additionally, prostaglandin analog activity may stimulate melanogenesis, contributing to darker hair appearance.
Robust clinical data support the efficacy of Latisse. In a multicenter, randomized, double-masked, vehicle-controlled study published in the Journal of the American Academy of Dermatology, bimatoprost demonstrated statistically significant improvements in eyelash growth and prominence compared to placebo, confirming its biologic effect on follicular stimulation. Furthermore, a pivotal Phase 3 clinical trial involving 278 patients showed that 78% experienced a measurable increase in eyelash prominence after 16 weeks of treatment, based on the Global Eyelash Assessment scale. Secondary endpoint data revealed that patients achieved lashes that were approximately 25% longer, 106% fuller, and 18% darker at 16 weeks, with visible improvements beginning as early as 4–8 weeks. These findings provide strong, peer-reviewed and clinical trial evidence supporting the consistent real-world outcomes observed in dermatology practices.
While Latisse is FDA-approved for eyelashes, its mechanism of action has led to widespread off-label use for eyebrow enhancement, particularly in patients with thinning brows due to over-plucking, aging, hormonal changes, or dermatologic conditions. Clinical experience suggests that when applied carefully to the brow area, bimatoprost can stimulate dormant follicles and improve hair density, offering a non-invasive alternative to eyebrow transplantation.
Ideal candidates for Latisse include individuals with sparse or thinning eyelashes or eyebrows who desire a gradual, natural enhancement. It is also appropriate for patients recovering from hair loss related to medical treatments or skin conditions, provided they are evaluated by a qualified medical professional. Because Latisse is a prescription medication with potential side effects—such as skin darkening or mild irritation—treatment should always be guided by experienced clinicians.
At Kare Plastic Surgery in Santa Monica, patients benefit from a multidisciplinary team of board-certified dermatologists, plastic surgeons, and skilled medical aestheticians who specialize in comprehensive facial and hair restoration treatments. This collaborative approach ensures that each patient receives a customized treatment plan tailored to their anatomy, aesthetic goals, and medical history. Whether addressing eyelash hypotrichosis or eyebrow thinning, the team provides expert evaluation, precise prescribing, and ongoing monitoring to maximize safety and results.
With its scientifically proven mechanism and strong clinical evidence, Latisse represents a gold standard in non-surgical hair enhancement. Under the care of experienced specialists, patients in Santa Monica can achieve fuller, darker, and more youthful-looking lashes and brows with a treatment that is both effective and medically validated.